Fig. 3.

Time course response for IGA (0,1) with ≥ 2-point reduction from baseline. Percentage of patients (%) with IGA 0,1 and ≥ 2-point reduction from baseline through 52 weeks. A total of 62.6% of patients (N = 129) achieved IGA 0 or 1 with ≥ 2-point reduction from baseline at Week 52. Missing data due to lack of efficacy were imputed with non-responder imputation. Other missing data were imputed with multiple imputation. Abbreviations: IGA Investigator’s Global Assessment, LEBRI lebrikizumab, Q2W every 2 weeks